Wuxi Biologics (Cayman) (2269) Stock Forecast & Price Target

Compare

42 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

2269 Analyst Ratings

Moderate Buy

1 Buy

1 Hold

0 Sell

Based on 2 analysts giving stock ratings to

Wuxi

Biologics (Cayman)

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

2269 Stock 12 Month Forecast

Average Price Target

HK$25.67

▼(-0.52%Downside)

Based on 2 Wall Street analysts offering 12 month price targets for Wuxi Biologics (Cayman) in the last 3 months. The average price target is HK$25.67 with a high forecast of HK$28.00 and a low forecast of HK$23.40. The average price target represents a -0.52% change from the last price of HK$25.80.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"HK$9","14":"HK$14","19":"HK$19","24":"HK$24","29":"HK$29"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":28.0000000049168,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$28.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25.6661826504,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$25.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.40000000410904,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$23.40</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,14,19,24,29],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.65,25.830769231147446,26.01153846229489,26.192307693442338,26.373076924589782,26.55384615573723,26.734615386884677,26.91538461803212,27.09615384917957,27.276923080327016,27.45769231147446,27.638461542621908,27.819230773769352,{"y":28.0000000049168,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.65,25.65124481926154,25.652489638523075,25.653734457784616,25.654979277046152,25.656224096307692,25.65746891556923,25.65871373483077,25.659958554092306,25.661203373353846,25.662448192615383,25.663693011876923,25.66493783113846,{"y":25.6661826504,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.65,25.476923077239157,25.30384615447831,25.13076923171747,24.957692308956627,24.78461538619578,24.61153846343494,24.438461540674098,24.265384617913256,24.09230769515241,23.91923077239157,23.746153849630726,23.57307692686988,{"y":23.40000000410904,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.74,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.14,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.18,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.42,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.88,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.5,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.32,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.5,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.56,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.48,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.45,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.8,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.65,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetHK$28.00

Average Price TargetHK$25.67

Lowest Price TargetHK$23.40

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

HK$26

Buy

0.78%

Upside

Reiterated

05/29/25

Wuxi Biologics demonstrates strong financial performance with robust growth and profitability, which is the primary driver of its score. Technical indicators show neutral momentum, while its valuation reflects a premium on expected growth. The lack of earnings call data and corporate events did not impact this analysis.

Nico ChenDBS

DBS

HK$24→HK$23.4

Hold

-9.30%

Downside

Reiterated

07/02/25

Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN), Wuxi Biologics (Cayman) (Other OTC: WXIBF) and HealthStream (NASDAQ: HSTM)

Yang HuangJ.P. Morgan

J.P. Morgan

HK$32→HK$28

Buy

8.53%

Upside

Reiterated

05/06/25

Wuxi Biologics (2269:HK) (WXXWY) PT Lowered to HK$28 at JPMorganJPMorgan analyst Yang Huang lowered the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$28.00 (from HK$32.00) while maintaining a Overweight rating.

Cui CuiJefferies

Jefferies

HK$45

Buy

74.42%

Upside

Reiterated

03/31/25

Wuxi Biologics (Cayman) (WXIBF) Receives a Buy from Jefferies

John YungCiti

Citi

HK$30→HK$35

Buy

35.66%

Upside

Reiterated

03/31/25

Wuxi Biologics (2269:HK) (WXXWY) PT Raised to HK$35 at CitiCiti analyst John Yung raised the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$35.00 (from HK$30.00) while maintaining a Buy rating.

Jill WuCMB International Securities

CMB International Securities

HK$24.24→HK$30.94

Buy

19.92%

Upside

Reiterated

03/27/25

WuXi Biologics: Strong Growth and Strategic Expansion Drive Buy Rating and Target Price Increase

Michael Luo CFACLSA

CLSA

HK$26→HK$28.8

Buy

11.63%

Upside

Reiterated

03/27/25

Wuxi Biologics (2269:HK) (WXXWY) PT Raised to HK$28.80 at CLSACLSA analyst Michael Luo raised the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$28.80 (from HK$26.00) while maintaining a Outperform (2) rating.

Ziyi ChenGoldman Sachs

Goldman Sachs

HK$20.8→HK$23.4

Hold

-9.30%

Downside

Reiterated

03/27/25

Wuxi Biologics (2269:HK) (WXXWY) PT Raised to HK$23.40 at Goldman SachsGoldman Sachs analyst Ziyi Chen raised the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$23.40 (from HK$20.80) while maintaining a Neutral rating.

Unknown AnalystUOB Kay Hian

Not Ranked

UOB Kay Hian

HK$35

Buy

35.66%

Upside

Reiterated

03/27/25

Jialin ZhangNomura

Nomura

HK$30.59→HK$34.36

Buy

33.18%

Upside

Reiterated

03/26/25

Wuxi Biologics (2269:HK) (WXXWY) PT Raised to HK$34.36 at Nomura/InstinetNomura/Instinet analyst Jialin Zhang raised the price target on Wuxi Biologics (2269:HK) (OTC: WXXWY) to HK$34.36 (from HK$30.59) while maintaining a Buy rating.

Tony RenMacquarie

Macquarie

HK$27

Hold

4.65%

Upside

Reiterated

03/26/25

Macquarie Reiterates Neutral Rating on Wuxi Biologics (2269:HK) (WXXWY)Macquarie analyst Tony Ren reiterated a Neutral rating and HK$27.00 price target on Wuxi Biologics (2269:HK) (OTC: WXXWY).

Sean Wu CFAMorgan Stanley

Morgan Stanley

HK$32

Buy

24.03%

Upside

Reiterated

08/30/24

Morgan Stanley Reiterates Overweight Rating on Wuxi Biologics (2269:HK) (WXXWY)Morgan Stanley analyst Sean Wu reiterated an Overweight rating and HK$32.00 price target on Wuxi Biologics (2269:HK) (OTC: WXXWY).

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

HK$26

Buy

0.78%

Upside

Reiterated

05/29/25

Nico ChenDBS

DBS

HK$24→HK$23.4

Hold

-9.30%

Downside

Reiterated

07/02/25

Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN), Wuxi Biologics (Cayman) (Other OTC: WXIBF) and HealthStream (NASDAQ: HSTM)

Yang HuangJ.P. Morgan

J.P. Morgan

HK$32→HK$28

Buy

8.53%

Upside

Reiterated

05/06/25

Cui CuiJefferies

Jefferies

HK$45

Buy

74.42%

Upside

Reiterated

03/31/25

Wuxi Biologics (Cayman) (WXIBF) Receives a Buy from Jefferies

John YungCiti

Citi

HK$30→HK$35

Buy

35.66%

Upside

Reiterated

03/31/25

Jill WuCMB International Securities

CMB International Securities

HK$24.24→HK$30.94

Buy

19.92%

Upside

Reiterated

03/27/25

WuXi Biologics: Strong Growth and Strategic Expansion Drive Buy Rating and Target Price Increase

Michael Luo CFACLSA

CLSA

HK$26→HK$28.8

Buy

11.63%

Upside

Reiterated

03/27/25

Ziyi ChenGoldman Sachs

Goldman Sachs

HK$20.8→HK$23.4

Hold

-9.30%

Downside

Reiterated

03/27/25

Unknown AnalystUOB Kay Hian

Not Ranked

UOB Kay Hian

HK$35

Buy

35.66%

Upside

Reiterated

03/27/25

Jialin ZhangNomura

Nomura

HK$30.59→HK$34.36

Buy

33.18%

Upside

Reiterated

03/26/25

Tony RenMacquarie

Macquarie

HK$27

Hold

4.65%

Upside

Reiterated

03/26/25

Macquarie Reiterates Neutral Rating on Wuxi Biologics (2269:HK) (WXXWY)Macquarie analyst Tony Ren reiterated a Neutral rating and HK$27.00 price target on Wuxi Biologics (2269:HK) (OTC: WXXWY).

Sean Wu CFAMorgan Stanley

Morgan Stanley

HK$32

Buy

24.03%

Upside

Reiterated

08/30/24

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Wuxi Biologics (Cayman)

1 Month

xxx

Success Rate

3/6 ratings generated profit

Average Return

+2.03%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +2.03% per trade.

3 Months

xxx

Success Rate

4/6 ratings generated profit

Average Return

+6.97%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +6.97% per trade.

1 Year

Jialin ZhangNomura

Success Rate

4/6 ratings generated profit

Average Return

+36.50%

reiterated a buy rating 3 months ago

Copying Jialin Zhang's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +36.50% per trade.

2 Years

xxx

Success Rate

4/6 ratings generated profit

Average Return

+44.52%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +44.52% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

2269 Analyst Recommendation Trends

Rating

Jan 25

Feb 25

Mar 25

May 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 2269 has received 8 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. 2269 average Analyst price target in the past 3 months is 25.67.

Each month's total comprises the sum of three months' worth of ratings.

2269 Financial Forecast

2269 Earnings Forecast

Next quarter’s earnings estimate for 2269 is HK$0.49 with a range of HK$0.49 to HK$0.49. The previous quarter’s EPS was HK$0.25. 2269 beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 39.17% of the time in the same period. In the last calendar year 2269 has Preformed in-line its overall industry.

2269 Sales Forecast

Next quarter’s sales forecast for 2269 is HK$10.66B with a range of HK$10.66B to HK$10.66B. The previous quarter’s sales results were HK$10.96B. 2269 beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 48.89% of the time in the same period. In the last calendar year 2269 has Preformed in-line its overall industry.

2269 Stock Forecast FAQ

What is HK:2269’s average 12-month price target, according to analysts?

Based on analyst ratings, Wuxi Biologics (Cayman) Inc.’s 12-month average price target is 25.67.

What is HK:2269’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for HK:2269, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Wuxi Biologics (Cayman) Inc. a Buy, Sell or Hold?

Wuxi Biologics (Cayman) Inc. has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 1 hold ratings and 0 sell ratings.

What is Wuxi Biologics (Cayman) Inc.’s share price target?

The average share price target for Wuxi Biologics (Cayman) Inc. is 25.67. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is HK$28.00 ,and the lowest forecast is HK$23.40. The average share price target represents -0.52% Decrease from the current price of HK$25.8.

What do analysts say about Wuxi Biologics (Cayman) Inc.?

Wuxi Biologics (Cayman) Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.

How can I buy shares of Wuxi Biologics (Cayman) Inc.?

To buy shares of HK:2269, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Wuxi Biologics (Cayman) (2269) Stock Forecast & Price Target

2269 Analyst Ratings

2269 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Wuxi Biologics (Cayman)

2269 Analyst Recommendation Trends

2269 Financial Forecast

2269 Earnings Forecast

2269 Sales Forecast

2269 Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts